A Study of ZN-c3 in Patients With Ovarian Cancer

Inclusion Criteria:

• Histologically or cytologically confirmed high-grade serous epithelial ovariancarcinoma, fallopian tube, or peritoneal carcinoma.

• Subjects must have received 1 or 2 prior therapeutic regimens/lines of therapy inthe advanced or metastatic setting.

• Measurable disease per RECIST version 1.1.

• Adequate hematologic and organ function as defined by the following criteria:

1. ANC ≥ 1.5 × 10^9/L; excluding measurements obtained within 7 days after dailyadministration of filgrastim/sargramostim or within 3 weeks afteradministration of pegfilgrastim.

2. Platelet count ≥ 100 × 10^9/L; excluding measurements obtained within 3 daysafter transfusion of platelets or within 3 weeks after administration ofplatelet growth factors.

3. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × upperlimit of normal (ULN). If liver function abnormalities are due to underlyingliver metastases, AST and ALT ≤ 5 x ULN.

4. Total serum bilirubin ≤ 1.5 × ULN or ≤ 3 × ULN in the case of Gilbert'sdisease.

5. Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 60 mL/min.

Exclusion Criteria:

• Histology of abdominal adenocarcinoma of unknown origin or diagnosis of a borderlineovarian tumor.

• Any of the following treatment interventions within the specified time frame priorto Cycle 1 Day 1:

1. Major surgery within 28 days.

2. Radiation therapy within 21 days.

3. Autologous or allogeneic stem cell transplant within 3 months.

A serious illness or medical condition(s) including, but not limited to, the following:

1. Brain metastases that require immediate treatment or are clinically orradiographically unstable.

2. Myocardial impairment of any cause.

3. Significant gastrointestinal abnormalities.

4. Active or uncontrolled infection.

5. Any evidence of small bowel obstruction as determined by air/fluid levels oncomputed tomography (CT) scan, recent hospitalization for small bowel obstructionwithin 3 months prior to Cycle 1 Day 1, or recurrent paracentesis or thoracentesiswithin 6 weeks prior to Cycle 1 Day 1.

• Subjects with active (uncontrolled, metastatic) second malignancies orrequiring therapy.